Curated News
By: NewsRamp Editorial Staff
September 09, 2025
Helix BioPharma to Present at Q3 Investor Summit, Highlighting NSCLC Trial
TLDR
- Helix BioPharma's presentation and NASDAQ uplisting offer investors early access to an undervalued microcap with strong oncology growth catalysts.
- Helix will present its Phase Ib/II L-DOS47 study for NSCLC and planned Q1 2026 NASDAQ uplisting at the September 16 Investor Summit.
- Helix's oncology innovations aim to turn hard-to-treat cancers into manageable conditions, improving patient outcomes and future cancer care.
- Helix CEO presents at an exclusive investor summit, highlighting groundbreaking cancer treatments and the company's upcoming NASDAQ listing plans.
Impact - Why it Matters
This news matters because Helix BioPharma's developments in oncology could significantly impact cancer treatment, particularly for non-small cell lung cancer, which is one of the most common and deadly cancers worldwide. The company's innovative approach with L-DOS47 aims to make hard-to-treat cancers more manageable, potentially offering new hope to patients with limited options. Additionally, the planned NASDAQ uplisting could provide greater access to capital, accelerating research and bringing these therapies to market faster. For investors, this represents an opportunity to support cutting-edge medical advancements while potentially benefiting from the growth of a company addressing critical unmet needs in healthcare.
Summary
Helix BioPharma Corp., a clinical-stage oncology company trading on TSX, OTC, and Frankfurt exchanges, is set to present at the Q3 2025 Investor Summit Virtual on September 16, 2025. The event, organized by Investor Summit Group, focuses on undervalued microcap companies with strong growth catalysts. Helix will highlight its upcoming Phase Ib/Randomized Phase II clinical study of L-DOS47 in combination with pembrolizumab for first-line treatment of non-small cell lung cancer (NSCLC), as well as its planned NASDAQ uplisting in Q1 2026. CEO Thomas Mehrling, MD, PhD, will lead the presentation and be available for one-on-one meetings with investors.
The company's pipeline is led by L-DOS47, a Tumor Defense Breaker™ antibody-enzyme conjugate designed to enhance sensitivity of CEACAM6-expressing tumors to therapy. Additionally, Helix is developing next-generation bi-specific antibody-drug conjugates and two pre-IND candidates: LEUMUNA™, an oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, an oral gemcitabine prodrug with IV-comparable bioavailability. The presentation will be accessible via webcast, with free registration available through the Investor Summit Group website, which connects high-quality small and microcap companies with institutional investors and high-net-worth individuals.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Helix BioPharma to Present at Q3 Investor Summit, Highlighting NSCLC Trial
